Pricing Log in Create free account
Saturday 17 October 2026 Export AHG’s income statement to Excel — free account

Akso Health Group Sponsored ADR

AHG Healthcare Medical Distribution

Akso Health Group Sponsored ADR’s revenue for fiscal 2026 (year ended March 2026) was $13.8 million, down 6.40% from fiscal 2025.

1.35 0.00 0.00%
Market cap
$1.2B
P/E
0.0×
Fwd P/E
0.0×
Dividend yield
—
F-score
5/9
Altman Z
112.75
Beneish M
n/a
Dividend safety
n/a
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Dec 25 Mar 26 Jun 26 Sep 26
Buy — — — — — — — — — — — —
Sell — — — — — — — — — — — —
Insider Ownership 0.00%

Capital & Financial Ratios $m

Market Cap 1,150.00
Revenue 20.14
Net Income 15.61
Free Cash Flow (160.20)
Net Debt (11.13)
Current Ratio 1.53 (at or above 1.5: strong)
Debt/Equity 0.00 (at or below 0.5: strong)
P/E ratio 0.00
Fwd P/E 0.00
P/S ratio 1.09
P/B ratio 0.11
Past 5Y EPS Growth —
This Y EPS Growth —
Next Y EPS Growth —
Next Y revenue growth (100.00%) (below 0%: weak)
Next 5Y EPS Growth —

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years
EV/Sales is 1.8×, against a ten-year median of 1.8×; over the ten years it ranged from −2.7× in 2024 to 11.3× in 2021.
P/S against its own 10 years 31.58%
10-year low 10-year high
P/B against its own 10 years 9.60%
10-year low 10-year high
EV/Sales against its own 10 years 41.63%
10-year low 10-year high

Dividends

Payout Ratio —
Annual Dividend Rate —
Annual Dividend Yield —
total individual payouts
2022 Powerpack
2021 Powerpack
2020 Powerpack
2019 Powerpack
2018 0.39
0.39
special payouts not included in total or ratios

Assets vs Liabilities $m

2023 2024 2025 2026
Cash 8 85 176 0
Receivables 8 — 13 1
Inventory 2 0 0 0
Other — — — 176
20 142 196 190
2023 2024 2025 2026
Payables — — — —
ST’ Debt — — — 0
Other 0 0 10 4
12 4 14 9

Compound Annual Growth %

10y 5y 3y
Sales 1.52% 51.12% 1.62%
Cash Flow 0.00% 0.00% 0.00%
Earnings 0.00% 0.00% 0.00%
Book Value 29.15% 59.97% 173.54%

Revenue $m

Mar Jun Sep Dec Year
’26 — — — — —
’26 — — — — 14
’25 — — — — 15
’24 — — — — 2
’23 — — — — 13
’22 — — — — 6
’21 — — — — 2
Fiscal quarters ending in the months shown.

Operating Cash Flow $m

Mar Jun Sep Dec Year
’26 — — — — —
’26 — — 1 — (13)
’25 — — (5) — 1
’24 — — — — 1
’23 — — — — (3)
’22 — — — — (9)
’21 — — — — 10
Fiscal quarters ending in the months shown.

Free Cash Flow $m

Mar Jun Sep Dec Year
’26 — — — — —
’26 — — (174) — (188)
’25 — — (5) — 1
’24 — — 0 — 1
’23 (2) — (1) — (3)
’22 (9) — 1 — (9)
’21 — — — — 10
Fiscal quarters ending in the months shown.

EPS $

Mar Jun Sep Dec Year
’26 — — — — —
’26 — — — — (0.03)
’25 — — — — (0.48)
’24 — — — — —
’23 — — — — (0.02)
’22 — — — — (0.28)
’21 — — — — (0.71)
Fiscal quarters ending in the months shown.
value withheld pending a data check

Target Price Range

Analyst price targets

Recommendation Rating

1Buy 2 3Hold 4 5Sell

Ten years at a glance Fiscal years to March

Group Line 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 Trend 2027e 2028e 2029e
Price, $
Price, $ Low 32.40 5.61 1.20 0.77 1.23 0.20 0.25 0.60 0.83 0.68

Analyst estimates 2027–2029

Powerpack
High 51.00 40.56 12.30 7.44 22.39 2.34 2.11 2.90 2.10 2.50
People
People Employees 295 400 552 182 113 42 12 9 9 12
Revenue/emp, $m 0.08 0.27 0.11 0.04 0.02 0.14 1.10 0.27 1.64 1.15
Income, $m
Income, $m Revenue 23 107 61 7 2 6 13 2 15 14
Gross margin, % 100.00 100.00 100.00 100.00 100.00 10.09 9.63 5.06 (1.90) (0.08)
EBT 10 77 7 (47) (31) (4) (13) (9) (166) (21)
EBT margin, % 44.04 71.36 12.07 (677.90) (1,770.43) (66.81) (99.13) (376.58) (1,125.14) (149.69)
Net income 9 66 6 (47) (32) (4) (13) (9) (135) (19)
Depreciation 0 0 0 0 0 0 — — 2 2
Per share, $
Per share, $ Revenue 1.62 7.15 3.78 0.43 0.11 0.30 0.58 0.05 0.05 0.02
Earnings 0.61 4.38 0.33 (4.38) (0.71) (0.28) (0.02) (0.07) (0.48) (0.03)
Cash flow 0.58 5.85 (0.11) (3.59) 0.62 (0.43) (0.14) 0.03 0.00 (0.02)
Capex (0.02) (0.03) (0.06) (0.01) 0.00 0.00 0.00 0.00 0.00 (0.24)
Free cash flow 0.56 5.82 (0.16) (3.60) 0.62 (0.43) (0.14) 0.03 0.00 (0.26)
Book value 1.67 9.34 7.79 2.96 1.06 0.62 0.39 2.93 0.70 0.25
Shares, m 14 15 16 16 16 20 23 47 285 723
Valuation, ×
Valuation, × P/E 7.48 7.88 27.83 0.00 0.00 0.00 0.00 0.00 0.00 0.00
P/S 0.00 4.79 2.65 1.32 2.56 3.43 0.30 0.92 0.95 1.84
P/B 4.99 3.67 1.29 0.20 1.66 2.24 0.67 3.48 0.10 0.19
EV/Sales 0.00 3.56 2.04 1.69 3.05 3.28 0.96 1.49 (2.36) 2.51
EV/FCF 4.94 3.57 1.37 0.62 0.81 0.65 (1.37) (2.12) (3.52) (0.32)
Cash, $m
Cash, $m Operating cash flow 8 88 (2) (58) 10 (9) (3) 1 1 (13)
Capex 0 0 (1) 0 — 0 — — 0 (176)
Free cash flow 8 87 (3) (58) 10 (9) (3) 1 1 (188)
Balance, $m
Balance, $m Working capital 23 139 71 40 16 12 9 138 182 181
Total debt — — 20 21 10 — — — — 0
Net debt (19) (133) (37) 14 (5) (18) (8) (85) (176) 0
Shareholders’ equity 24 140 127 48 17 12 9 138 199 181
Returns, %
Returns, % ROA 60.40 68.11 3.28 (56.12) (62.10) (35.67) (3.27) (11.64) (75.62) (9.23)
ROIC 145.03 639.06 3.57 (48.36) (159.07) 0.00 (974.52) (10.14) (453.47) (7.14)
ROE 45.69 80.08 4.15 (81.55) (106.55) (114.02) (12.87) (12.85) (79.97) (9.83)
Negative figures in brackets.

All 10 years →

Fiscal years to Mar 2026 · latest quarter Sep 2019

Charts ten years each

Akso Health Group Sponsored ADR vs peers in Medical Distribution (Q) = latest quarter vs a year earlier

Company Market cap P/E Fwd P/E Revenue growth (Q) EPS growth (Q) FCF growth (Q) Gross margin (Q) EBIT margin (Q) Compare
COR Cencora, Inc. $65.2B 25.2× 14.5× +5.07% (above 0%: growing) +11.27% (above 0%: growing) +3,385.25% (above 0%: growing) 4.26% 1.32% Compare
CAH Cardinal Health, Inc. $58.8B 35.0× 23.3× +5.84% (above 0%: growing) +68.32% (above 0%: growing) +10.87% (above 0%: growing) 4.02% 1.14% Compare
HSIC Henry Schein, Inc. $9.7B 25.0× 18.5× +6.73% (above 0%: growing) +16.90% (above 0%: growing) +140.91% (above 0%: growing) 31.84% 4.95% Compare
AHG Akso Health Group Sponsored ADR $1.2B — (loss-making) — (loss-making) +263.89% (above 0%: growing) n/m −12,975.04% (below 0%: shrinking) 0.00% 0.00%
FOCL FocalTherics $154.8M — (loss-making) — (loss-making) +38.85% (above 0%: growing) n/m +21.49% (above 0%: growing) 55.59% (60.83%) Compare
COSM Cosmos Health Inc. $33.9M — (loss-making) 25.1× +28.76% (above 0%: growing) n/m +9.39% (above 0%: growing) 7.96% (15.41%) Compare
ACH Accendra Health, Inc. $20.1M — (loss-making) — (loss-making) −10.07% (below 0%: shrinking) n/m −1,624.82% (below 0%: shrinking) 42.95% (5.73%) Compare
HKPD Cellyan Biotechnology Co., Ltd $17.1M — — — — −90.45% (below 0%: shrinking) — — Compare
YI 111, Inc. Sponsored ADR $16.0M — (loss-making) — (loss-making) −29.61% (below 0%: shrinking) n/m −185.70% (below 0%: shrinking) 5.33% (0.85%) Compare
Median of peers $94.3M 25.2× 20.9× +5.84% +16.90% +10.13% 7.96% (0.85%)

All 11 Medical Distribution stocks →

Akso Health Group Sponsored ADR (AHG) key facts

  • Concern: Akso Health Group Sponsored ADR’s revenue for fiscal 2026 (year ended March 2026) was $13.8 million, down 6.40% from fiscal 2025.
  • Akso Health Group Sponsored ADR (AHG) is a Medical Distribution company in the Healthcare sector, listed on Nasdaq.
  • As of October 16, 2026, AHG traded at $1.35, a market capitalization of $1.2 billion.
  • Return on equity was −9.83% and debt-to-equity 0.00.
  • Its Piotroski F-score is 5 out of 9 and its Altman Z-score is 112.75 (safe zone) for fiscal 2026.

Source: company filings (standardised) and stockrow calculations.

Akso Health Group Sponsored ADR (AHG) Latest News

No news at this impact. Lower the threshold for more.
stockrow.com/AHG · Data as of Sep 30, 2019 · For information only; not investment advice. · © 2026 stockrow.com